What do systematic reviews say?

Pulse cyclophosphamide vs continuous cyclophosphamide

Pulse cyclophosphamide may leads to higher relapse at the end of compared with continuous cyclophosphamide (low certainty).

• Interventions for renal vasculitis in adults 2020 · Cochrane Headline outcomes only
  RR 1.79 [1.11, 2.87]
  4 studies · 235 participants
  Low

Pulse cyclophosphamide vs continuous cyclophosphamide

Pulse cyclophosphamide showed no clear difference in adverse events ‐ treatment failure compared with continuous cyclophosphamide (low certainty).

• Interventions for renal vasculitis in adults 2020 · Cochrane Headline outcomes only
  RR 1.36 [0.115, 12.56]
  2 studies · 82 participants
  Low

Pulse cyclophosphamide vs continuous cyclophosphamide

Pulse cyclophosphamide showed no clear difference in serious infections compared with continuous cyclophosphamide (low certainty).

• Interventions for renal vasculitis in adults 2020 · Cochrane Headline outcomes only
  RR 0.71 [0.38, 1.33]
  4 studies · 278 participants
  Low

Rituximab vs cyclophosphamide

Rituximab showed no clear difference in death at 6 months compared with cyclophosphamide (moderate certainty).

• Interventions for renal vasculitis in adults 2020 · Cochrane Headline outcomes only
  RR 1 [0.21, 4.7]
  2 studies · 241 participants
  Moderate

Rituximab vs cyclophosphamide

The review found no eligible studies for this question.

• Interventions for renal vasculitis in adults 2020 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Rituximab vs cyclophosphamide

The review found no eligible studies for this question.

• Interventions for renal vasculitis in adults 2020 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Rituximab vs cyclophosphamide

Rituximab showed no clear difference in remission at 6 months compared with cyclophosphamide (moderate certainty).

• Interventions for renal vasculitis in adults 2020 · Cochrane Headline outcomes only
  RR 1.02 [0.79, 1.32]
  2 studies · 236 participants
  Moderate

Rituximab vs cyclophosphamide

Rituximab showed no clear difference in relapse at 12 months compared with cyclophosphamide (low certainty).

• Interventions for renal vasculitis in adults 2020 · Cochrane Headline outcomes only
  RR 1.43 [0.18, 11.31]
  1 study · 38 participants
  Low

Intervention not reported

• Interventions for renal vasculitis in adults 2020 · Cochrane Headline outcomes only
  no estimate extracted
  4 studies · 156 participants
  Low

Rituximab vs cyclophosphamide

Rituximab showed no clear difference in serious adverse events compared with cyclophosphamide (moderate certainty).

• Interventions for renal vasculitis in adults 2020 · Cochrane Headline outcomes only
  RR 1.11 [0.72, 1.71]
  2 studies · 241 participants
  Moderate

Rituximab vs cyclophosphamide

Rituximab showed no clear difference in serious Infections compared with cyclophosphamide (moderate certainty).

• Interventions for renal vasculitis in adults 2020 · Cochrane Headline outcomes only
  RR 0.89 [0.62, 1.92]
  2 studies · 241 participants
  Moderate

Mycophenolate mofetil vs cyclophosphamide

Mycophenolate mofetil showed no clear difference in death at 6 months compared with cyclophosphamide (low certainty).

• Interventions for renal vasculitis in adults 2020 · Cochrane Headline outcomes only
  RR 1.25 [0.35, 4.46]
  1 study · 140 participants
  Low

Mycophenolate mofetil vs cyclophosphamide

The review found no eligible studies for this question.

• Interventions for renal vasculitis in adults 2020 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Mycophenolate mofetil vs cyclophosphamide

Mycophenolate mofetil showed no clear difference in dialysis compared with cyclophosphamide (low certainty).

• Interventions for renal vasculitis in adults 2020 · Cochrane Headline outcomes only
  RR 1 [0.14, 6.9]
  1 study · 140 participants
  Low

Mycophenolate mofetil vs cyclophosphamide

Mycophenolate mofetil showed no clear difference in relapse at any time point compared with cyclophosphamide (low certainty).

• Interventions for renal vasculitis in adults 2020 · Cochrane Headline outcomes only
  RR 1.8 [1, 3.22]
  1 study · 127 participants
  Low

Mycophenolate mofetil vs cyclophosphamide

Mycophenolate mofetil probably leads to higher remission at 6 months compared with cyclophosphamide (moderate certainty).

• Interventions for renal vasculitis in adults 2020 · Cochrane Headline outcomes only
  RR 1.17 [1.01, 1.35]
  3 studies · 216 participants
  Moderate

Mycophenolate mofetil vs cyclophosphamide

Mycophenolate mofetil may leads to higher serious adverse events compared with cyclophosphamide (low certainty).

• Interventions for renal vasculitis in adults 2020 · Cochrane Headline outcomes only
  RR 1.25
  1 study · 140 participants
  Low

Mycophenolate mofetil vs cyclophosphamide

Mycophenolate mofetil showed no clear difference in infection compared with cyclophosphamide (moderate certainty).

• Interventions for renal vasculitis in adults 2020 · Cochrane Headline outcomes only
  RR 1.27 [0.75, 2.16]
  3 studies · 216 participants
  Moderate

IVIg vs placebo

Intravenous immunoglobulin showed no clear difference in death compared with placebo (low certainty).

• Interventions for renal vasculitis in adults 2020 · Cochrane Headline outcomes only
  RR 0.2 [0.01, 3.88]
  1 study · 34 participants
  Low

Intervention not reported

The intervention may leads to lower dialysis at one year (low certainty).

• Interventions for renal vasculitis in adults 2020 · Cochrane Headline outcomes only
  RR 0.45 [0.29, 0.72]
  6 studies · 235 participants
  Low